Article in Cancer immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
33 authors.
Emily BontekoeDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0880-1721
Minying ZhangDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0006-0345-2469
Peixin JiangDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0005-8033-1639
Amanda MontoyaDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0001-2055-5084
Barbara Nassif RausseoDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7772-2456
Changsheng XingDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6582-9037
David P MolkentineDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0505-6815
Benjamin B MorrisDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7415-7703
Isabella PolicDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0007-9566-1803
Janos RoszikDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4561-6170
Aria VaishnaviDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-7814-3234
Drew DenigerDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9299-9688
Hai T TranDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4065-9355
Don L GibbonsDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2362-3094
Ara VaporciyanDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2060-3584
Maura L GillisonDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8145-5749
Ignacio I WistubaDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3365-6340
Lydia E KavrakiDepartment of Computer Science, Rice University, Houston, Texas.ORCID 0000-0003-0699-8038
Jianjun ZhangDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7872-3477
Gregory LizeeDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4449-7461
Cassian YeeDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4429-7307
Patrick HwuDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-8293-1313
Alex M JaegerDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-4319-4330
John V HeymachDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9068-8942
Alexandre ReubenDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4510-0382
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Translational Genomics and Precision Medicine in Cancer Training ProgramT32CA217789 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Subrata Sen · 2018 to 2026
$2.2M
Time-lapse Flow Cytometry for Kinetic Profiling of T-Cell FunctionR44CA281529 · NCI · LASE INNOVATION INC. · PI KWOK, SHELDON J.J. · 2023 to 2024
$1.8M
NovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995k
Unbiased electrothermal flow-enhanced identification of antigen-specific T cells in lung cancerR21CA283852 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LILLEHOJ, PETER B, REUBEN, ALEXANDRE · 2023 to 2023
$413k
FY2025 SBIR CONCEPT CLEARANCE AWARD FOR TOPIC DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS.75N91025C00012 · NCI · TENACI-T THERAPEUTICS LLC · 2025 to 2025
$353k
American Association for Cancer Research (AACR) 23-20-01-REUBAmerican Lung Association (ALA)Bruce Campbell Research GrantCancer Prevention and Research Institute of Texas (CPRIT) RP210137Cancer Prevention and Research Institute of Texas (CPRIT) RP230363Cancer Prevention and Research Institute of Texas (CPRIT) RP260357EGFR ResistersExon20 GroupGil and Dody Weaver Foundation and Bill and Katie Weaver Charitable TrustHappy Lungs ProjectLance Bertrand Research GrantLUNGevity Foundation (LUNGevity)National Cancer Institute (NCI) P30CA016672National Cancer Institute (NCI) P30CA076292National Cancer Institute (NCI) R21CA283852National Institutes of Health (NIH) 1S10OD024977-01National Institutes of Health (NIH) R44CA281529NCI NIH HHS 75N91025C00012NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA076292NCI NIH HHS R21 CA283852NCI NIH HHS R44 CA281529NCI NIH HHS T32 CA217789NIH HHS S10 OD024977Petrin FundRETpositiveRexanna's Foundation (Rexanna Foundation for Fighting Lung Cancer)Salgado Family Charitable FundThe University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson's Lung Cancer Moon ShotTroper Wojcicki FoundationU.S. Department of Defense (DOD) HT9425-23-1-1021Waun Ki Hong Lung Cancer Research Fund
6 · The paper itself
Abstract
FOXM1 is highly expressed in various cancer types and considered a key driver of cancer progression. Accordingly, we evaluated the immunogenicity of FOXM1 and investigated the feasibility of targeting this transcription factor using T-cell receptor (TCR) engineering. We identified epitopes derived from FOXM1 which were immunogenic on HLA-A*02:01, HLA-A*24:02, and HLA-A*23:01, endogenously processed and presented, and resulted in T-cell activation and cytotoxic T-cell responses. Following the generation of TCR-T cells, sensitivity and specificity were confirmed by peptide dose-response and X-scan, respectively. Most importantly, adoptive transfer of TCR-engineered T cells led to a significant reduction in tumor growth, as well as significantly prolonged survival in a tumor-bearing immunocompromised murine model. Our studies confirm the immunogenicity of FOXM1 and feasibility of targeting this antigen using TCR engineering.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer. · full record | OpenQuestion